| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Mark S Cohen last filed a Form 4 in June 2016, as Director at AKTX. Mark S Cohen's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 1,055,600 shares of AKTX. Net of sales, the AKTX filings show accumulation of 1,055,600 shares.
Mark S Cohen has 4 Form 4 filings on record from January 2015 to June 2016, all as Director at Akari Therapeutics (AKTX), 2015–2016.
The 7 reported transactions were 4 option or other derivative awards, 2 option exercises and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $200K and no sales.
The only open-market purchase was 1,055,600 shares of AKTX at an average $0.19 on September 18, 2015, about $200K.
Shares as reported in the last Form 4 for each company; the most recent is from June 2016. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 18, 2015 | AKTX Akari Therapeutics Plc | Director | Buy | 1,055,600 | $0.19 | $200,036.20 | New |